Physician profile
Kye B Lear
NPI 1255394094
$3,683.60
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $1,026 · 2021: $1,152 · 2022: $33.61 · 2023: $63.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $63.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $63.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.55 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $432.17 | 2019-2021 | |
| Pfizer INC. | $403.47 | 2019-2023 | |
| Lilly USA, LLC | $309.70 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.05 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $233.90 | 2019-2021 | |
| Allergan, INC. | $174.09 | 2019-2020 | |
| Amarin Pharma, INC. | $137.70 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $122.77 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.85 | 2021 | |
| Astellas Pharma US INC | $111.27 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.96 | 2020-2021 | |
| Glaxosmithkline, LLC. | $106.52 | 2019-2021 | |
| Esperion Therapeutics, INC. | $105.67 | 2020-2021 | |
| Genentech USA, INC. | $98.00 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $76.35 | 2019 | |
| Supernus Pharmaceuticals, INC. | $63.85 | 2019-2020 | |
| Amgen INC. | $56.96 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $50.33 | 2019-2021 | |
| Novo Nordisk INC | $40.07 | 2019 | |
| Eisai INC. | $37.66 | 2019 | |
| Tactile Systems Technology INC | $33.22 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $26.83 | 2021 | |
| Mylan Specialty L.P. | $26.24 | 2020 | |
| Antares Pharma, INC. | $25.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.39 | 2019 | |
| Alfasigma USA, INC. | $12.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kye Lear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.